TAK, US8740602052

Takeda Pharmaceutical stock: TradingView lifts target for Takeda Pharmaceutical stock to USD 20.74

Published on 10/23/2026 at 15:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda reports JPY 1.22 trillion in fiscal 2027 first-quarter revenue. Takeda Pharmaceutical stock costs EUR 18.00 on October 23, 2026.

Analyst target and reporting date

TradingView reported a rise in the average target from USD 20.58 to USD 20.74 on October 15, 2026.
Takeda reported JPY 1.22 trillion in revenue for the first quarter of fiscal 2027.
Takeda stock costs EUR 18.00 at Lang & Schwarz on October 23, 2026 at 3:03 p.m. CEST.
Takeda will present second-quarter fiscal 2026 results on October 29, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical (ISIN US8740602052) has a new average analyst target of USD 20.74, up from USD 20.58, while the current euro quotation stands at EUR 18.00. TradingView reported the target change on October 15, 2026, citing estimates from 14 analysts. The target lies 1.87 percent above the NYSE close of USD 20.36 on October 22, 2026. At Lang & Schwarz, Takeda stood at EUR 18.00 on October 23, 2026 at 3:03 p.m. CEST.

Analysts lift the average target

The target change is modest in relation to the US quotation, but it gives investors a concrete benchmark ahead of Takeda's next scheduled results. TradingView reported a forecast range of USD 16.96 to USD 23.36 per share and said the consensus rating remained Buy across 17 covering analysts, including 10 Buys and 7 Holds.

Revenue reaches JPY 1.22 trillion

Takeda's operating picture includes a large first-quarter revenue base. Yahoo Finance lists revenue of JPY 1.22 trillion and earnings of JPY 113.2 billion for the first quarter of fiscal 2027, with a profit margin of 9.28 percent. Yahoo Finance also identifies Takeda's business across gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.

NYSE range sets the market frame

Takeda closed at USD 20.36 on the NYSE on October 22, 2026, within a 52-week range of USD 12.99 to USD 20.39. The upper end was only USD 0.03 above that close, while the market capitalization stood at USD 65.0 billion and volume reached 3,461,926 shares. The stock's year-to-date performance was 30.26 percent.

Results date comes next

Takeda has scheduled its second-quarter fiscal 2026 results for October 29, 2026. In its release dated October 15, 2026, Takeda said the presentation and question-and-answer session would take place on the same day, with the investor webcast scheduled for 7:00 p.m. to 8:15 p.m. JST. The date gives the new target its next scheduled test.

Price remains the live marker

The analyst target, the first-quarter figures, and the October 29 reporting date create three separate reference points for the stock. The euro quotation remains the most immediate market marker for investors in Germany. Takeda was trading at EUR 18.00 at Lang & Schwarz on October 23, 2026 at 3:03 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Takeda Pharmaceutical stock.